Falsified meds rules respected
This article was originally published in OTC Bulletin & The Rose Sheet
Respecting the European Commission’s (EC’s) interpretation of the incoming Falsified Medicines Directive was the only way to avoid “market chaos”, according to the director general of the Association of the European Self-Medication Industry, the AESGP, Hubertus Cranz.
You may also be interested in...
Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.
First Circuit reverses dismissal of direct purchasers' suit alleging improper listing of patent on device drive mechanism delayed competition; district court to decide if this constitutes antitrust violation.
Brands unfairly attacked by powerful influencers could raise the subject with the US Federal Trade Commission, which is asking for comments on its “Endorsement Guides."